$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
The first RET inhibitor platinib in China is on the market!
2025-10-19 11:44:20
Check Details
How should I take icotinib to treat lung cancer? How long does it take for resistance to develop?
2025-10-19 11:44:20
Check Details
RET inhibitor with 85% effectiveness-serpatinib
2025-10-19 11:44:20
Check Details
The latest data on the new anti-cancer drug entrectinib are released, with an effective rate of 100%!
2025-10-19 11:44:20
Check Details
How long can a person with advanced lung cancer live after taking the targeted drug gefitinib? How much does a box cost in Hubei?
2025-10-19 11:44:20
Check Details
Mobotinib, the second targeted drug, approved to treat non-small cell lung cancer
2025-10-19 11:44:20
Check Details
What is Mobotinib? How to buy it?
2025-10-19 11:44:20
Check Details
Can Dacomitinib be used on an empty stomach? What should we pay attention to?
2025-10-19 11:44:20
Check Details
How effective is dacomitinib in treating lung cancer? How long does it usually take to take effect
2025-10-19 11:44:20
Check Details
How many years can patients with advanced lung cancer live on crizotinib? How much does crizotinib cost in Anhui?
2025-10-19 11:44:20
Check Details
How many months will it take for the tumor to disappear after taking crizotinib? What should I do if I have intolerance to side effects?
2025-10-19 11:44:20
Check Details
How many days does it take for Osimertinib to take effect? What does osimertinib do?
2025-10-19 11:44:20
Check Details
1
2
...
3964
3965
3966
3967
3968
3969
3970
...
4161
4162
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
2
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
3
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
4
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
5
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
6
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
7
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
8
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
9
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity
10
Tivozanib Dosing Guide for Renal Cell Carcinoma: 21-Day On/7-Day Off Cycle and Adjustments
11
Selpercatinib: Dosing and Administration Essentials of an Oral RET Inhibitor
12
Alpelisib: From Breast Cancer to PIK3CA-Related Overgrowth Spectrum